Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration.

• Peptide Vials (PT-141, 10 mg each):
  • 8 weeks (56 days × 500 mcg = 28 mg) ≈ 3 vials
  • 12 weeks (56 × 500 + 28 × 1000 = 56 mg) ≈ 6 vials
  • 16 weeks (56 × 500 + 28 × 1000 + 28 × 1500 = 98 mg) ≈ 10 vials
• Insulin Syringes (U-100):
  • Per week: 7 syringes (1/day)
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
  • 16 weeks: 112 syringes
• Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
  • 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle
  • 12 weeks (6 vials): 18 mL → 2 × 10 mL bottles
  • 16 weeks (10 vials): 30 mL → 3 × 10 mL bottles
• Alcohol Swabs: One for the vial stopper + one for the injection site each day.
  • Per week: 14 swabs (2/day)
  • 8 weeks: 112 swabs → recommend 2 × 100-count boxes
  • 12 weeks: 168 swabs → recommend 2 × 100-count boxes
  • 16 weeks: 224 swabs → recommend 3 × 100-count boxes

View Supplier

View Supplier

View Supplier

View Supplier

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes (27–30G, 5/8-inch needle) for each injection; dispose in a sharps container^[7].
• Rotate injection sites (abdomen, thighs) on different days to avoid lipodystrophy or irritation^[6].
• Inject slowly; wait a few seconds before withdrawing the needle.
• Nausea is the most common side effect and tends to be transient; flushing and headache may also occur^[3].
• Document daily dose and site rotation to maintain consistency.

How This Works

Bremelanotide is a synthetic analog of α-melanocyte-stimulating hormone that acts as a non-selective melanocortin receptor agonist, predominantly targeting MC3R and MC4R^[3]. In the central nervous system, MC4R activation enhances dopamine release in key brain reward and arousal regions including the nucleus accumbens and medial preoptic area, which increases sexual motivation and desire^[3]. Unlike PDE5 inhibitors, bremelanotide does not directly affect the nitric oxide pathway; in men, its erectogenic effect is secondary to this central mechanism stimulating nitric oxide production in penile tissue^[3]. Peripheral MC1R agonism accounts for side effects such as transient blood pressure elevation and skin hyperpigmentation (tanning)^[3][5].

Potential Benefits & Side Effects

Observations from clinical trials and peer-reviewed literature.

• Clinical trials in premenopausal women with HSDD demonstrated significant improvements in sexual desire scores (FSFI-Desire) and reduced distress (FSDS-DAO) versus placebo^[3].
• Early studies also suggest potential benefit in men, with intranasal PT-141 improving erectile responses and increasing arousal measures in women^[1].
• Adverse effects are usually mild and transient: most commonly nausea (~40%), flushing, headache, and injection-site reactions^[3][5].
• Transient increases in blood pressure have been reported; bremelanotide is not recommended for individuals with uncontrolled hypertension or cardiovascular disease^[5][10].
• Skin darkening (hyperpigmentation) may occur with repeated use due to peripheral MC1R activation and is generally reversible^[3].

Lifestyle Factors

Complementary strategies for best outcomes.

• Maintain a balanced diet and regular exercise routine to support overall hormonal health.
• Prioritize sleep quality, as poor sleep can negatively affect libido and hormonal balance.
• Manage stress through mindfulness, therapy, or relaxation techniques, as chronic stress can suppress sexual desire.
• Limit alcohol consumption, which may dampen the effects of melanocortin receptor activation.

Injection Technique

General subcutaneous guidance from clinical best-practice resources^[11].

• Clean the vial stopper and skin with alcohol; allow to dry^[7].
• Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue^[7][8].
• Do not aspirate for subcutaneous injections; inject slowly and steadily^[7].
• Rotate sites systematically (abdomen, thighs) to avoid lipohypertrophy^[6][11].
• Discard needles and syringes in a sharps container after one use^[7].

Intranasal (IN) Research Summary

Bremelanotide was initially developed and studied via the intranasal route before the subcutaneous formulation was selected for FDA approval. The following bullets summarize reported findings from peer-reviewed literature. This section reports study data only and does not constitute a protocol or recommendation.

• Route studied: Intranasal (IN) delivery via metered-dose nasal spray was the primary route in early-phase clinical trials of PT-141 for both male erectile dysfunction and female sexual arousal disorder (reported in studies)^[14][15].
• Male ED trials (human, RCT): A double-blind, placebo-controlled, at-home study in men with erectile dysfunction evaluated intranasal bremelanotide at administered amounts of 7 mg and 20 mg via nasal spray. The study reported statistically significant improvements in erectile function versus placebo (reported in studies)^[14].
• Female arousal trials (human, RCT): Intranasal bremelanotide was studied in premenopausal women with female sexual arousal disorder. Administered amounts of 20 mg IN were reported, with significant increases in subjective arousal and desire versus placebo (reported in studies)^[15].
• Bioavailability comparison: The subcutaneous route demonstrated approximately 100% bioavailability, whereas intranasal bioavailability was substantially lower and more variable across subjects. This pharmacokinetic limitation contributed to the selection of subcutaneous injection for the approved Vyleesi product (reported in studies)^[3][10].
• Blood pressure concerns: Intranasal administration was associated with more pronounced transient increases in blood pressure compared with subcutaneous delivery, which was a factor in the route switch during clinical development (reported in studies)^[10][16].
• Delivery form and device: Studies used aqueous solution delivered via a metered-dose nasal spray pump. Specific device specifications (delivered volume per actuation) were not consistently reported across publications^[14][15].
• Nausea incidence: Nausea was the most commonly reported adverse event with intranasal bremelanotide, occurring at higher rates with higher administered amounts. This side effect was also dose-limiting in some subjects (reported in studies)^[3][16].
• PK variability: Inter-subject variability in C_max and AUC was notably higher with the intranasal route than with subcutaneous injection, attributed to differences in nasal mucosal absorption, mucus clearance, and technique (reported in studies)^[3][17].
• Key limitation: The intranasal route for bremelanotide was ultimately not pursued for regulatory approval due to the combination of lower and more variable bioavailability, higher incidence of blood pressure elevation, and less predictable pharmacokinetics compared with the subcutaneous route (reported in studies)^[10][17].

Nasal Spray Device Output & Conversion Math

Important: Nasal spray pumps vary in delivered volume per actuation depending on manufacturer, model, and priming state. The mcg delivered per spray is entirely dependent on the specific device used. Always verify the delivered volume per actuation from the manufacturer’s specifications or by direct gravimetric measurement. This section provides a parameterized measurement framework only and does not suggest any particular administration regimen.

Parameterized Framework

Inputs:

• concentration_mcg_per_mL — peptide concentration after reconstitution (or convert: mg/mL × 1000 = mcg/mL)
• pump_output_mL_per_actuation — delivered volume per spray (from manufacturer specs or direct measurement)

Output:

• amount_mcg_per_actuation = concentration_mcg_per_mL × pump_output_mL_per_actuation

Optional Volume Mapping (U-100 Convention)

If “units” are used as a volume shorthand (where 100 units = 1.0 mL on a U-100 scale):

• pump_output_mL_per_actuation = units_per_actuation / 100
• amount_mcg_per_actuation = concentration_mcg_per_mL × (units_per_actuation / 100)

Nasal Actuation Calculation Table (Placeholders)

Worked Examples (Placeholders Only)

Example 1 (mL-based pump): If concentration = 3333 mcg/mL (i.e., 10 mg reconstituted in 3.0 mL) and pump output = 0.10 mL/actuation, then amount per actuation = 3333 × 0.10 = 333.3 mcg/spray. Actuations per mL = 1 / 0.10 = 10. Total actuations in 3.0 mL = 30.

Example 2 (units-based): If concentration = 3333 mcg/mL and pump delivers 13 units/actuation, then pump output = 13 / 100 = 0.13 mL. Amount per actuation = 3333 × 0.13 = 433.3 mcg/spray. Actuations per mL = 1 / 0.13 ≈ 7.7. Total actuations in 3.0 mL ≈ 23.

These examples use the PT-141 10 mg / 3.0 mL reconstitution concentration for illustrative math only. They do not represent recommended administered amounts. Device-specific calibration is essential.